OSL:VISTN • NO0010734122
Past quarterly earnings results for VISTIN PHARMA ASA (VISTN.OL), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Actual vs estimated values, surprises, q2q growth and acceleration numbers for recent quarters.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q3 2025 | - | - | 108.84M | - | 2.84% | |||
| Q2 2025 | - | - | 117.67M | - | 10.92% | |||
| Q1 2025 | - | - | 115.037M | - | 10.74% | |||
| Q4 2024 | - | - | 113.288M | - | 5.11% | |||
| Q3 2024 | - | - | 105.838M | - | -11.76% | |||
| Q2 2024 | - | - | 106.081M | - | -0.61% | |||
| Q1 2024 | - | - | 103.884M | - | 2.92% | |||
| Q4 2023 | - | - | 107.784M | - | 14.96% | |||
| Q3 2023 | - | - | 119.938M | - | 30.77% | |||
| Q2 2023 | - | - | 106.729M | - | 54.70% | |||
| Q1 2023 | - | - | 100.94M | - | 203.86% | |||
| Q4 2022 | - | - | 93.754M | - | 24.49% | |||
| Q3 2022 | - | - | 91.714M | - | 45.92% | |||
| Q2 2022 | - | - | 68.989M | - | 3.20% | |||
| Q1 2022 | - | - | 33.219M | - | -53.08% | |||
| Q4 2021 | - | - | 75.309M | - | 18.27% | |||
| Q3 2021 | - | - | 62.854M | - | 14.16% | |||
| Q2 2021 | - | - | 66.847M | - | -8.46% | |||
| Q1 2021 | - | - | 70.803M | - | 15.86% | |||
| Q4 2020 | - | - | 63.675M | - | - | |||
| Q3 2020 | - | - | 55.056M | - | - | |||
| Q2 2020 | - | - | 73.021M | - | - | |||
| Q1 2020 | - | - | 61.111M | - | - |
Notes
VISTIN PHARMA ASA (VISTN.OL) last reported earnings on 2/12/2026.
VISTIN PHARMA ASA (VISTN.OL) missed EPS estimates and missed revenue estimates in the most recent quarter.